



MTAP Deletion Biomarker: Changing Lung Cancer Treatment One Biomarker at a Time Show Notes

Doctors and researchers have known about a biomarker known as MTAP deletion for many years. But now they're learning what role this gene plays in lung cancer and other tumors. Long ago, this genetic alteration was thought to be just collateral damage that occurs in tumors, but now researchers are uncovering its influence on tumors. It turns out there are some advantages for a tumor to have this MTAP gene loss. This new understanding means new medications can likely be developed to open a new weak point in the tumor to allow for targeted therapy.



A Block Guest:

- Starting timecode:05
- Speaker bio: Jordi Rodon Ahnert, MD, Ph.D., medical oncologist at MD Anderson Cancer Center in Houston

Resources:

National Library of Medicine: <https://pubmed.ncbi.nlm.nih.gov/35747993>

Journal of Translational Medicine:

<https://translational-medicine.biomedcentral.com/articles/10.1186/s12967-022-03823-8#:~:text=Homozygous%20deletion%20of%20MTAP%20is.the%20MTAP%20promoter%20%5B9%5D>

Science: <https://www.science.org/doi/10.1126/science.aad5214>

LCFA's mission is the improvement in survivorship of lung cancer patients through the funding of transformative science.

While raising funds to support lung cancer research, LCFA will raise the public's awareness and serve as a resource for patients or anyone seeking answers, hope, and access to updated treatment information, scientific investigation, and clinical trials.

You can also join the conversation with LCFA on [Facebook](#), [Twitter](#), and [Instagram](#).